MicroRNAs (miRNAs) are short non-coding RNAs (ncRNAs) of ~18-25 nucleotides that are present in all eukaryotic cells and play important roles in almost all biological signaling pathways.1, 2, 3, 4 Since the discovery of the first miRNA (lin-4) in
More recently, miRNAs have been found to be specifically present in mitochondria. These mitochondrial miRNAs were named “mitomiR”.7, 29, 30, 31, 32 Most of them have a nuclear origin, but some mitomiRs originate from mRNA molecules derived from the mitochondrial genome. The association of mitomiRs with mitochondria is species- and cell type-specific.7, 33 They have been found in mitochondria in various tissues and cells and are thought to have different thermodynamic properties than miRNAs.7, 34 Mitochondria have a discrete and unique pool of mitomiRs, which has been demonstrated with various experiments.29
For the first time, in 2011, Barrey and co-workers demonstrated the presence of pre-miRNAs (precursor-miRNAs) in mitochondria and postulated that some pre-miRNA sequences could be processed into mature miRNAs that could immediately become active on mitochondrial transcripts or exported to the cytosol to disrupt genomic mRNA.35 Barrey’s group screened for 742 miRNAs using qRT-PCR and showed that 243 miRNAs had significant expression in mitochondrial RNA samples isolated from human myotubes by
MitomiRs have been shown to be important regulators of mitochondrial function.35, 38, 41 The regulation of mitochondria by mitomiRs influences the development of many diseases caused by mitochondrial dysfunction, which is responsible for the pathophysiology of numerous diseases, such as cardiovascular and neurodegenerative diseases, diabetes, obesity, and cancer.42
In the first part of this review article, we describe the biosynthesis of mitomiRs and the transport mechanisms from mitomiRs to mitochondria. The next part is dedicated to the role of these small molecules in mitochondria and the presentation of some important mitomiRs, their target genes and functions. In the last part of the review, we discuss the functions of mitomiRs in cancer cell metabolism and introduced mitomiRs in the context of cancer.
Most miRNAs/mitomiRs are produced via the canonical biosynthetic pathway, which involves transcription by RNA polymerase II (Pol II) to produce a primary transcript (pri-miRNA/mitomiR). The primary transcript is first cleaved in the nucleus by the nuclear heterodimer Drosha/DGCR8 (DiGeorge syndrome chromosomal region 8), which cleaves the pri-miRNA/mitomiR and produces a pre-miRNA/mitomiR with a hairpin structure that is much more stable than the pri-miRNA/ mitomiR due to its characteristic hairpin loop structure.43 Exportin 5 (EXP5) and GTP-binding nuclear protein (RANGTP) then form a transport machinery to export the pre-miRNA from the nucleus to the cytoplasm. After export to the cytoplasm, the pre-miRNA/mitomiR is further cleaved by the enzyme Dicer to form a double-stranded RNA (dsRNA) duplex (Figure 1). Only a single strand of the dsRNA duplex forms the mature miRNA/mitomiR and is incorporated into the RNA-induced silencing complex (RISC), which directs the binding of Argonaute (AGO) proteins in the RISC to the 3’UTR of the target mRNA to either repress protein translation or promote mRNA degradation.43, 44, 45 After incorporation into RISC, mature miRNA/mitomiRs are transported into mitochondria, back to nucleus by importin 8 (IPO-8) or extracellular environment (Figure 1).46, 47
In addition to the canonical miRNAs/mitomiRs biosynthesis pathway, there are also non-canonical, Drosha/DGCR8-independent and Dicer-independent biosynthesis pathways. Prominent classes of Drosha/DGCR8-independent miRNAs/ mitomiRs are the “mirtrons” derived from introns that, once spliced, function as pre-miRNAs and thus do not require cleavage by Drosha/DGCR8 and can be immediately exported to the cytoplasm for processing by Dicer. MiRNAs/mitomiRs can also be processed from hairpins generated directly by Pol II at specific transcription start sites. These pre-miRNAs are capped and exported via the exportin 1 (EXP1) pathway. The Dicer-independent miRNAs/mitomiRs biosynthesis pathway involves the unusually short hairpin of miR-451, which is directly cleaved by argounaute 2 (AGO2).45
The discovery of mitomiRs raised the question of elucidating the underlying molecular mechanisms of their transport into mitochondria. Due to their size and charged nature, mitomiRs are unlikely to cross membranes under their own power. The molecular mechanisms of mitomiR transport into mitochondria may vary between species and are not well understood.29
Some proposals have been published on AGO2 as a potential mitomiR import protein.7, 29, 48 Due to its RNA-binding ability and dual localization in the cytosol and mitochondria, AGO2 might be involved in the trafficking of mitomiRs.7 Shepherd
Mitochondria are semi-autonomous cell organelles with their own DNA (mtDNA) encoding 22 tRNAs, 2 rRNAs, and 13 polypeptides. These polypeptides and those encoded by nuclear genes, form 4 protein complexes of the electron transport chain (ETC). Mitochondria are constantly dividing and fusing, and the balance between mitochondrial fission and fusion influences mitochondrial morphology, whose dynamics and turnover are critical for cellular homeostasis and differentiation.50 Several proteins are involved in the regulation of mitochondrial dynamics. Deregulation of mitochondrial dynamics is not only associated with deregulation of mitochondrial function, but is also closely related to several biological processes such as proliferation, cell death, apoptosis and production of reactive oxygen species (ROS), since mitochondria are the major sites of oxidative metabolism of sugars, lipids, amino acids and ATP production.1, 51, 52, 53
It’s also worth noting that the mitochondrial matrix has its own set of environmental variables. Because of its thioester bond, acetyl-coenzyme A (acetyl-CoA) is a very abundant metabolite in mitochondria and functions as a powerful acetylation reagent. Protein lysine acetylation and succinylation are caused by acetyl-CoA and mitochondrial matrix pH concentrations. Non-enzymatic acetylation occurs often in mitochondria.54 The most of mitochondrial proteins have acetyl groups, which is consistent with this hypothesis. Non-enzymatic acetylation of RNA molecules, including miRNAs, is a logical possibility for mitochondrial modification. An acetyl group covalently attached to a miRNA might change its mRNA recognition behavior. If it happens at the 2 OH group of ribose needed for the cleavage process, it could inhibit spontaneous bond cleavage and therefore increase the half-life of mRNA. Furthermore, post-transcriptional alterations can result in structural changes55 as well as changed interactions with other RNA molecules or proteins.56
As stated, mitomiRs are regulators of mitochondrial function, as shown in the following examples.
Summary of microRNAs and their roles in mitochondria
miR | miR accession number | Target genes | Gene accession number | Function | Functional pathway | Location | Species | References |
---|---|---|---|---|---|---|---|---|
miR-378 | MI0000795 | Crat | ENSMUSG00000026853 | Downregulation | Mitochondrial oxidative metabolism | Mitochondria in liver cells | Mouse | Carrer |
miR-24 | MI0000080 | H2ax | ENSMUSG00000049932 | Downregulation | Insulin pathway signaling | Mitochondria liver cells in | Human | Jeong |
miR-23b | MI0000439 | GLS | ENSG00000115419 | Downregulation | Glutamine metabolism | LMitochondria liver cells in | Human | Gao |
SLC2A1 | ENSG00000117394 | Downregulation | ||||||
miR-1291 | MI0006353 | CPT1C ESRRA | ENSG00000169169 ENSG00000173153 | Downregulation Downregulation | Mitochondrial | Mitochondria in | Human | Yamasaki |
ASS1 | ENSG00000130707 | Downregulation | metabolism | renal cells | 2020, Tu |
|||
GLUT1 | ENSG00000117394 | Downregulation | ||||||
miR-138 | MI0000455 | PDK1 | ENSG00000152256 | Downregulation | Glucose metabolism | Mitochondria in cardiac cells | Human | Zhu |
miR-150 | MI0000920 MI0000479 | Slc2a4 SLC2A1 | ENSRNOG00000017226 ENSG00000117394 | Downregulation Downregulation | Metabolism | Mitochondria in cardiac cells | Rat Human | Ju |
Slc2a4 | ENSRNOG00000017226 | Upregulation | Mitochondria in | |||||
miR-199a | MI0000941 | Hk2 | ENSRNOG00000006116 | Upregulation | Expression of | muscle cells | Rat | Esteves |
MI0000242 | HK2 | ENSG00000159399 | Upregulation | glucose transporters | Mitochondria in liver cells | Human | ||
miR-532-5p | MI0006154 | SlcHk22 a4 | ENSRNOGENSRNOG00000017226 00000006116 | Upregulation Upregulation | Expression glucose transporters of | Mitochondria muscle cells in | Rat | Esteves |
Mitochondrial | Mitochondria in | |||||||
miR-29a | MI0000576 | Slc16a1 | ENSMUSG00000032902 | Downregulation | oxidative metabolism | pancreatic betacells | Mouse | Pullen |
miR-29b | MI0000143 | Slc16a1 | ENSMUSG00000032902 | Downregulation | Mitochondrial oxidative metabolism | Mitochondria in pancreatic betacells | Mouse | Pullen |
Mitochondrial | Mitochondria in | |||||||
miR-124 | MI0000716 | Slc16a1 | ENSMUSG00000032902 | Downregulation | oxidative | pancreatic beta- | Mouse | Pullen |
metabolism | cells | |||||||
CROT | ENSANAG00000028065 | Downregulation | ||||||
CPT1A | ENSANAG00000017356 | Downregulation | ||||||
HADHB | ENSANAG00000027802 | Downregulation | ||||||
PRKAA1 | ENSANAG00000032687 | Downregulation | ||||||
miR-33a/b | a-MI0002684, b-MI0007603 | ABCA1 | ENSANAG00000033387 | Downregulation | Lipid metabolism | Mitochondria in liver cells | Monkey | Rayner |
SREBF1 | ENSANAG00000021477 | Upregulation | ||||||
FASN | ENSANAG00000032055 | Upregulation | ||||||
ACLY | ENSANAG00000036009 | Upregulation | ||||||
ACACA | ENSANAG00000035253 | Upregulation | ||||||
miR-143 | MI0000916 | Map2k5 | ENSRNOG00000007926 | Downregulation | Adipogenesis | Mitochondria in adipose cells | Rat | Chen |
MI0000459 | APOL6 | ENSG00000221963 | Downregulation | Adpiogenesis | Mitochondria in adipose cells | Human | Ye |
|
miR-204 | MI0000284 | ACACB | ENSG00000076555 | Downregulation | Lipid metabolism | Mitochondria adipose cells in | Human | Civelek |
miR-200 | MI0000737 | ZEBZEB1 2 | ENSGENSG00000148516 00000169554 | Upregulation Upregulation | Lipid metabolism | Mitochondria breast cells in | Human | Ahmad |
miR-338 | MI0000618 | COXIV | ENSRNOG00000007827 | Downregulation | Mitochondria oxidative metabolism | Mitochondria in neural cells | Rat | Aschrafi |
miR-181c | MI0000924 | COX1 | ENSRNOG00000034234 | Downregulation | Mitochondria oxidative metabolism | Mitochondria in cardiac cells | Rat | Das |
miR-210 | MI0000268 | ISCU | ENSG00000136003 | Downregulation | Mitochondria oxidative metabolism | Mitochondria in placenta cells | Human | Colleoni |
miR-15b | MI0000843 | Arl2 | ENSRNOG00000021010 | Downregulation | ATP production | Mitochondria in cardiac cells | Rat | Nishi |
Bcl2 | ENSRNOG00000002791 | Downregulation | ||||||
miR-16 | MI0000844 | Bcl2 | ENSRNOG00000002791 | Downregulation | ATP production | Mitochondria in cardiac cells | Rat | Nishi |
Arl2 | ENSRNOG00000021010 | Downregulation | ||||||
miR-195 | MI0000939 | Arl2 | ENSRNOG00000021010 | Downregulation | ATP production | Mitochondria in cardiac cells | Rat | Nishi |
miR-29a-3p | MI0000576 | Foxa2 | ENSMUSG00000037025 | Upregulation | Lipid metabolism | Mitochondria liver cells in | Mouse | Kurtz |
miR-19b | MI0000074 | MFN1 | ENSG00000171109 | Downregulation | Apoptosis | Mitochondria in bone cells | Human | Li |
miR-101-3p | MI0000103 | ATP5B | ENSG00000110955 | Silencing | Mitochondria metabolism | Mitochondria heLa cells in | Human | Zheng |
The microRNAs listed in Table 1 significantly affect mitochondrial regulation and function, which is why they are classified in the group of mitomiRs, which are crucial regulatory molecules of mitochondrial function and regulation of metabolism. In the figures (Figure 2 and Figure 3), we have shown how these mitomiRs are linked to their target genes in primates (Figure 2) and rodents (Figure 3).
In primates, there is no regulation of the same genes by different mitomiRs from Table 1 (Figure 2). Moreover, most mitomiRs target one gene and only a few mitomiRs target a larger number of genes and in most cases mitomiRs down-regulate genes.
In contrast to primates, in rodents, some genes are regulated by different mitomiRs (Figure 3). The mitomiRs miR-15b and miR-16 both regulate the
From the figures (Figure 2 and Figure 3), we can summarize that some mitomiRs and their target genes are related in primates and rodents. MitomiR miR-199a69, 70 regulates the same gene in both primates and rodents (Figure 3), the gene
Traditional cancer traits include ten biological capabilities gained during the multistage development of human tumors.89 These ten traditional cancer traits include resistance to cell death, induction of angiogenesis, maintenance of proliferative signaling, evasion of growth suppressors, activation of invasion and metastasis, facilitation of replicative immortality, altered metabolism, evasion of destruction by the immune system, tumorpromoting inflammation, and genome instability (Figure 4).89, 90
An important feature of cancer is the presence of the Warburg effect. Under aerobic conditions, normal cells generate ATP primarily in the mitochondrial oxidative phosphorylation process (OXPHOS), which utilizes the products of glycolysis and the Krebs cycle. Under anaerobic conditions, relatively little pyruvate, the end product of glycolysis, is added to the Krebs cycle and is instead converted to lactate. However, this metabolic conversion of glucose appears to be energetically detrimental. In tumor cells, ATP deficiency can be compensated to some extent by upregulation of glycolysis.91 Interestingly, it has been observed that many cancer cells prefer glycolysis over OXPHOS even in the presence of an adequate amount of oxygen. This abnormal energy metabolism is known as the Warburg effect. Reduced OXPHOS and enhanced aerobic glycolysis are the main manifestations of reprogramming of glucose metabolism in tumor cells.1, 92 Albeit the specific causes and utilitarian outcomes of this metabolic switch are as yet unclear, there is a developing agreement that the impact of Warburg effect is certifiably not an inconsequential result of carcinogenesis, yet is imperative for cancer cells to keep up with their proliferative potential and is driven by a few elements.92, 93, 94
It has been confirmed that abnormal expression of mitomiRs in mitochondria is related to the occurrence of cancer features.95 Moreover, mitomiRs play an essential role in the control of cancer cell metabolism by regulating mRNA expression. They regulate several oncogenic signaling pathways and target key transporters or enzymes in cellular metabolism. In addition, they may have a function as tumor suppressors that inhibit tumor cell proliferation or as oncogenes that induce tumorigenesis.96, 97, 98 MitomiRs can be isolated from any tissue or body fluid of any organism to study the level of expression in the organism in a diseased state, and thus can function as novel prognostic and predictive biomarkers.99
The first evidence of miRNA involvement in human cancers was provided in a study of chronic lymphocytic leukemia (CLL).100 MiR-15a and miR-16-1 localized to 13q14 were reported to be frequently deleted and/or reduced in patients with B-cell chronic lymphocytic leukemia. This finding provided the first evidence that miRNAs may be involved in the pathogenesis of human cancers, as deletion of chromosome 13q14 resulted in the loss of these two miRNAs. MiR-15a induces apoptosis by regulating mitochondrial function and affecting the activity of Bcl-2 and Mcl-1 in human (Table 2). In addition, miR-15a causes mitochondrial dysfunction, leading to the release of cytochrome c into the cytoplasm and depletion of mitochondrial membrane potential.101 MiR-15a and miR-16a have been shown to be ATP modulators correlated with cytochrome c oxidase subunit 4I2 (Cox4i2), subunit 6A2 (Cox6a2), NADH:ubiquinone oxidoreductase subunit B7 (Ndufb7), NADH:ubiquinone oxidoreductase core subunit V1 (Ndufv1) and NADH:ubiquinone oxidoreductase subunit S4 (Ndufs4) expression.102
Summary of mitomiRs with roles in cancer
miR | miR accession number | Target genes | Gene accession number | Function | Functional pathway | Type of cancer | Species | References |
---|---|---|---|---|---|---|---|---|
HIF-1 | ENSG00000258777 | Upregulation | ||||||
ISCU | ENSG00000136003 | Upregulation | ||||||
miR-210 | MI0000286 | COX10 | ENSG00000006695 | Upregulation | Hypoxia | Breast cancer, neck and head cancer, lung cancer | Human | Qin |
SDHD | ENSG00000204370 | Upregulation | ||||||
NDUFA4 | ENSG00000189043 | Upregulation | ||||||
miR-200a | MI0000342 | TFAM | ENSG00000108064 | Downregulation | Mitochondrial biogenesis, cancer metabolism | Breast cancer | Human | Yao |
miR-155 | MI0000681 | HK2 | ENSG00000159399 | Upregulation | phosphorylation Glucose | Breast cancer | Human | Jiang Fang |
miR-124 | MI0000443 | PKM | ENSG00000067225 | Upregulation | metabolism Glucose | Colorectal cancer | Human | Sun |
miR-137 | MI0000454 | PKM | ENSG00000067225 | Upregulation | metabolism Glucose | Colorectal cancer | Human | Sun |
miR-340 | MI0000802 | PKM | ENSG00000067225 | Upregulation | metabolism Glucose | Colorectal cancer | Human | Sun |
miR-326 | MI0000808 | PKM2 | ENSG00000067225 | Downregulation | metabolism Glucose | Glioblastoma | Human | Kefas |
miR-181-5p | MIMAT0000256 | RASSF6 |
ENSG00000169435 |
Downregulation |
Mitogen-activated protein kinase (MAPK) signaling pathway | Gastric cancer, cervical cancer | Human | Mi |
miR-92a-1 | MI0000093 | BCL2L11 | ENSG00000153094 | Downregulation | Apoptosis | Lymphoma | Human | Mogilyansky Rigoutsos, 2013 and 94 |
PIK3R2 | ENSG00000105647 | Downregulation | Breast cancer cells | Zhu |
||||
PLK2 | ENSG00000260410 | Downregulation | Acute leukaemia cells | Li |
||||
EGFL7 | ENSG00000172889 | Downregulation | Oral squamous cells | Sasahira |
||||
CRK | ENSG00000167193 | Downregulation | Lung cancer cells | Crawford 2008117 |
||||
ADAM9 | ENSG00000168615 | Downregulation | Melanoma cells cancer | Felli |
||||
miR-126 | MI0000471 | HOXA9 | ENSG00000078399 | Downregulation | Inflammation, angiogenesis | Acute leukaemia cells | Human | Shen |
IRS1 | ENSG00000169047 | Downregulation | Breast cancer cells | Zhang |
||||
SOX-2 | ENSG00000242808 | Downregulation | Gastric cells cancer | Otsubo |
||||
SLC7A5 | ENSG00000103257 | Downregulation | Lung cancer cells | Miko |
||||
VEGFA | ENSG00000150630 | Downregulation | Oral squamous cells | Sasahira |
||||
MMP7 | ENSG00000137673 | Downregulation | Melanoma cells cancer | Felli |
||||
BCL-2 | ENSG00000171791 | Downregulation | ||||||
Gao |
||||||||
MCL-1 | ENSG00000143384 | Downregulation | ||||||
COX4I2 | ENSG00000131055 | Downregulation | ||||||
miR-15a | MI0000069 | COX6A2 | ENSG00000156885 | Downregulation | Apoptosis, ATP production | B-cell chronic lymphocytic leukemia | Human | Siengdee |
NDUFB7 | ENSG00000099795 | Downregulation | 2010102 | |||||
NDUFV1 | ENSG00000167792 | Downregulation | ||||||
NDUFS4 | ENSG00000164258 | Downregulation | ||||||
COX4I2 | ENSG00000131055 | Downregulation | ||||||
COX6A2 | ENSG00000156885 | Downregulation | ||||||
miR-16a | MI0000070 | NDUFB7 | ENSG00000099795 | Downregulation | Apoptosis, ATP production | B-lymphocytic cell chronic leukemia | Human | Siengdee |
NDUFV1 | ENSG00000167792 | Downregulation | ||||||
NDUFS4 | ENSG00000164258 | Downregulation |
Glycolysis is the initial step in glucose catabolism, and occurs outside of the mitochondria in the cytoplasm. In the context of miRNAs affecting cell metabolism, miR-155 (Table 2) was found to indirectly upregulate hexokinase 2 (HK2), a glucose phosphorylation enzyme that might affect energy consumption in breast cancer cells. Mir-143 appears to be one of two potential pathways regulating miR-155-dependent HK2 regulation.103, 104 Alternative splicing of pyruvate kinase isoenzyme (PKM), whose splicing proteins are regulated by miR-124, miR-137, and miR-340, is another pathway regulating glucose metabolism (Table 2). This miRNA-dependent regulation of PKM is able to influence colorectal cancer growth and counteract the Warburg effect.105 In addition, pyruvate kinase (PK) is a direct target of the tumor suppressor miR-326, making it a potential glucose metabolism regulator.94, 106, 107
In hepatocellular carcinoma, reduced mRNA levels were detected in 11 of the 13 genes encoded in the mtDNA, including the genes encoding cytochrome B (mt-CYB) and cytochrome C oxidase II (mt-CO2).108 When miR-181a-5p expression was increased, the levels of mt-CYB and mt-CO2 were reduced in hepatocellular carcinoma cells, while mitochondrial membrane potential (MMP) maintained by electron transfer chain was reduced.
Several studies reported that miR-126 has an important role in different human cancers (Table 2) such as breast, lung, gastric cancers, melanoma cancer and acute leukaemia. Tomasetti
Hypoxia has previously been related to altered mitomiR expression, with hypoxia-regulated mitomiRs being found to play a key role in cell survival in oxygen-depleted settings.123 MiR-210 is one of the mitomiRs that is continuously increased in normal and transformed cells during hypoxia, suggesting that miR-210 plays a role in cells’ adaptive response to hypoxia.109 MiR-210 expression corresponds with hypoxia gene signatures in tumor tissues such as breast and head and neck cancers, demonstrating a direct connection between miR-210 expression and hypoxia in cancer.110 MiR-210 has been researched extensively and has a number of functionally significant targets in cell cycle control, cell survival, differentiation, angiogenesis, and metabolism.123 Cell metabolism switches from mitochondrial OXPHOS to glycolysis under hypoxic environments. HIF-1, a hypoxia-inducible factor that upregulates the expression of most glycolytic enzymes as well as pyruvate dehydrogenase kinase while downregulating mitochondrial respiration, plays a key role in this action. Previous research has looked into how miR-210 regulates mitochondrial metabolism under hypoxia. MiR-210 target iron-sulfur cluster assembly proteins (ISCU1/2) and inhibit the activity of iron-sulfur proteins that govern mitochondrial metabolism, such as complex I and aconitase, resulting in lower OXPHOS.123 It acts directly on cytochrome c oxidase assembly factor heme A:farnesyltransferase (COX10), succinate dehydrogenase complex subunit D (SDHD), and NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4 (NDUFA4) in regulating mitochondrial activity.123 Another study found an abnormal mitochondrial phenotype in A549 lung cells overexpressing miR-210, and mRNA expression profile analysis connecting miR-210 to mitochondrial dysfunction.112 Interestingly, HIF is rapidly destroyed upon reoxygenation of hypoxic cells due to miR-210’s high stability, whereas miR-210 stays stable to maintain the glycolytic phenotype. Under normal conditions, this slows mitochondrial metabolism and may contribute to the Warburg effect in cancer cells. This result supports miR-210’s involvement in regulating mitochondrial metabolism and promoting cancer cells’ adaptability to hypoxic environments.
Another important mitomiR is miR-200, which has been identified as involved in tumor progression.124, 125 One of miR-200 targets, is transcription factor mitochondria (TFAM) which is one of the most important proteins regulating mitochondrial biogenesis. TFAM has been described as a functional target of miR-200 in breast cancer cells.113 Its transcription factor activity is required for mtDNA replication and transcription. In addition to its function in replication and transcription, the presence of TFAM is necessary for mtDNA maintenance.126 It has also been implicated as a primary architectural protein of the mitochondrial genome by packaging mtDNA. In addition, TFAM expression has been reported to be involved in tumor progression, cancer cell growth, and chemoresistance.127
Regarding the role of miRNAs in cancer and metabolism, the miR-17/92 cluster is one of the best characterized oncogenic miRNAs. This cluster is also known as oncomiR-1, and there is growing evidence of its oncogenic potential.93 It has been shown that miR-17/92 suppresses apoptosis and was originally found amplified in B-cell lymphomas, where ectopically overexpressed truncated versions lacking miR-92a-1 were shown to possess oncogenic properties.110 The MiR-17/92 cluster is deregulated in B-cell lymphomas, T-cell lymphomas, B-cell chronic lymphocytic leukemia, and acute myeloid leukemia. This cluster is particularly overexpressed in several other cancers, including osteosarcoma, neuroblastoma, cervical, pancreatic, breast, lung, colorectal, ovarian, kidney, and liver cancers.93, 105 Izreig
MiRNAs have been found in the mitochondria of many cell types, as shown by an increasing number of studies and they were named mitomiRs. In general, mitomiR populations differ in various tissues and under different pathological circumstances, implying that mitomiR populations are regulated by mechanisms that remain to be discovered. Based on the available information, we can deduce that there are a significant number of miR-NAs which are present in mitochondria.7, 29, 30, 31, 32, 33
In our review, we have shown that various mitomiRs play a role in the initiation and progression of cancer via the regulation of mitochondria.
They are involved in the Warburg effect, which is necessary for cancer cells to maintain their proliferative capacity.91 MitomiRs also upregulate HK2, a glucose phosphorylation enzyme, in an indirect manner, which may impact energy consumption in breast cancer cells.103, 104 Expression of one of the mitomiRs (miR-210) corresponds with hypoxia gene signatures in tumor tissues such as breast cancer and head and neck cancers, demonstrating a clear connection between mitomiR expression and hypoxia in cancer.108, 109, 121 MiRNAs have emerged in the last decade as key regulators in cancer-related processes and are classified as either oncogenic or tumor suppressive miRNAs. The miR-17/92 cluster was first discovered to be amplified in diffuse cell lymphoma and B-cell lymphoma. This mitomiR cluster suppresses apoptosis and may act as an oncogene in B-cell lymphomas, B-cell chronic lymphocytic leukemia, acute myeloid leukemia, and T-cell lymphomas. It is also overexpressed in numerous other malignancies. This cluster is a key factor in metabolic reprogramming of tumors by regulating glycolytic and mitochondrial metabolism. Tumor-targeting treatments based on mitomiRs are emerging as a novel diagnostic and therapeutic tool.94, 106, 111, 128
We have shown that mitomiRs are important players in mitochondria of cancer cell that need to be further investigated to develop a new potential therapies for cancer. Numerous studies that have been published in recent years give promising predictions that mitomirRs will receive more attention in the context of their role in cancer as possible bio-markers or targets for treatment.